No Data
JXR: Annual Report 2024
Market Participants Recognise Jinxin Fertility Group Limited's (HKG:1951) Earnings Pushing Shares 28% Higher
JXR (1951.HK): Steadily advancing, the penetration rate of IVF continues to increase.
The population issue is increasingly becoming a key topic of concern for countries around the world.
Hong Kong stock movement | JXR (01951) surged nearly 5% during the session. Institutions indicated that the company benefits from stimulus policies with significant growth in overseas business.
JXR (01951) surged nearly 5% during the trading session, up 4.5% as of the time of writing, priced at 3.25 Hong Kong dollars, with a transaction value of 0.0106 million Hong Kong dollars.
News Flash: 13 Analysts Think Jinxin Fertility Group Limited (HKG:1951) Earnings Are Under Threat
[Brokerage Focus] BOCOM INTL maintains a Buy rating on JXR (01951) with a more optimistic expectation for performance in 2026 and the long term.
Gold Eagle Financial News | BOCOM INTL Research Reports indicate that JXR (01951) expects a revenue growth of 1% and a decline of 12% in adjusted Net income for 2024. The number of cycles in Chengdu's Business decreased by 13%, but revenue saw a slight increase due to higher demand in obstetrics, pediatrics, and high-end Medical Services that drove up the ASP. Among the incubating Institutions, the number of cycles in Wuhan grew by 40%, while Yunnan remained essentially flat after excluding the impact of renovations. Overseas Business revenue and the number of cycles increased by 6% and 18% respectively. The bank noted that policy benefits are gradually being realized: Hohhot recently released the implementation details for childcare subsidies, and the bank expects more regions to follow suit.
Insider Spends CN¥3.6m Buying More Shares In Jinxin Fertility Group
